Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Originally posted on June 6, 2015 plus a current patent application as of February 23, 2017 -

"High-resolution, Integrated Molecular Profiling Reveals Persistent Inflammation in Kawasaki Disease Patients with Coronary Artery Aneurysms"
Date/Time: Friday, June 12, 2015 during the 10:30am-12:00pm CET session

As part of the Company's research on intravenous immunoglobulin (IVIG), Momenta applied its high-resolution biological analytics to identify biologies impacted by treatment, and biologies associated with clinical resolution of Kawasaki disease. This oral presentation describes Momenta's approach to identifying biomarkers associated with sub-clinical disease activity and provides insights into the mechanism of action of IVIG in this disease.

http://ir.momentapharma.com/releasedetail.cfm?releaseid=916467

Now the updated version from MNTA's patent applications dated -
2017-02-23

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF KAWASAKI DISEASE

The present invention relates to the determination of levels or expression of particular biomarkers in biological samples which can be utilized to diagnose, prognose, and treat Kawasaki disease in subjects, and further to select subjects who would benefit from a Kawasaki disease therapy other than, or in addition to, IVIG treatment. Accordingly, the present invention encompasses methods and compositions that utilize these biomarkers for the diagnosis, prognosis, and treatment of Kawasaki disease.

Read more:
https://worldwide.espacenet.com/publicationDetails/description?CC=US&NR=2017052200A1&KC=A1&FT=D&ND=3&date=20170223&DB=EPODOC&locale=en_EP